[1例HER2阳性乳腺癌伴肝转移患者对曲妥珠单抗联合帕妥珠单抗治疗显示三年完全缓解]
[A Case of HER2-Positive Breast Cancer with Liver Metastases Showing Three Years of Complete Response to Combination Therapy with Trastuzumabplus Pertuzumab].
作者信息
Fujimoto Yuri, Yamaguchi Kazushige, Ueno Ayako, Sakurai Reo, Nagahisa Yoshio, Imai Shiro, Kawamoto Kazuyuki
机构信息
Dept. of Surgery, Kurashiki Central Hospital.
出版信息
Gan To Kagaku Ryoho. 2018 Mar;45(3):459-461.
A 48-year-old woman with severe interstitial pneumonitis was diagnosed with right breast cancer(invasive ductal carcinoma, T1aN1M0, ER+, PgR-, HER2 3+)and underwent modified radical mastectomy.The patient was administered tamoxifen as adjuvant therapy.However, 1 year after the mastectomy, multiple liver metastases were found and the patient received 2 anti-HER2 agents, trastuzumab and pertuzumab.A complete response(CR)was observed with the disappearance of the liver metastases in 7 months.CR was maintained for 2 years after the initiation of treatment, and then, we started trastuzumab monotherapy, which has resulted in long-term disease control.
一名患有严重间质性肺炎的48岁女性被诊断为右乳腺癌（浸润性导管癌，T1aN1M0，雌激素受体阳性、孕激素受体阴性、人表皮生长因子受体2 3+），并接受了改良根治性乳房切除术。该患者接受他莫昔芬作为辅助治疗。然而，乳房切除术后1年，发现多处肝转移，患者接受了2种抗人表皮生长因子受体2药物，曲妥珠单抗和帕妥珠单抗。7个月时观察到肝转移灶消失，达到完全缓解（CR）。治疗开始后CR维持了2年，然后，我们开始曲妥珠单抗单药治疗，实现了疾病的长期控制。
Zotero 插件